BMC Pharmacology

, 9:P57 | Cite as

Nucleotidyl cyclase activity of recombinant soluble guanylyl cyclase

  • Kerstin Rauch
  • Johannes-Peter Stasch
  • Volkhard Kaever
  • Roland Seifert
Open Access
Poster presentation


Nitric Oxide Pulmonary Hypertension Nucleoside Uridine Nitroprusside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


The ubiquitously expressed soluble guanylyl cyclase (sGC) converts guanosine 5'-triphosphate (GTP) to guanosine 3':5'-cyclic monophosphate (cGMP). The heterodimeric protein is activated by nitric oxide (NO). sGC plays a key role in the regulation of vascular tone and neurotransmission. Hence, sGC is an important target for the treatment of cardiovascular diseases e.g. pulmonary hypertension, heart failure and coronary heart disease. In addition to the biosynthesis of cGMP, we had previously shown by radiochemical analysis that sGC also generates the cyclic pyrimidine nucleotide uridine 3':5'-cyclic monophosphate (cUMP)[1]. However, cUMP could only be described as putative product but an exact identification by structure analysis was still missing. Therefore, we have established a new analytical method based on high performance liquid chromatography/mass spectrometry (HPLC-MS/MS) [see poster: CM Spangler et al.]. In comparison with classic radiochemical assays an analysis by HPLC-MS/MS allows the detection of non-radioactive compounds. Accordingly, a broader spectrum of substrates that is not available for radioactive assays can be used. Additionally, different nucleotides can be detected at the same time and the detection is directly structure-based. Making use of the new HPLC-MS/MS method we systematically characterised the substrate specificity of sGC.

Materials and methods

Highly purified recombinant sGC from rat (α1β1) was activated by sodium nitroprusside (100 μM). sGC (5 ng/tube) was incubated at 37°C with 3 mM MnCl2 and 200 μM of various nucleoside 5'-triphosphates (NTPs). Samples were stopped by heating at 95°C after 20 minutes. Concentrations of adenosine 3':5'-cyclic monophosphate (cAMP), inosine 3':5'-cyclic monophosphate (cIMP), uridine 3':5'-cyclic monophosphate (cUMP), cytidine 3':5'-cyclic monophosphate (cCMP) and thymidine 3':5'-cyclic monophosphate (cTMP) were determined by HPLC-MS/MS.


We could demonstrate that besides GTP, sGC converts adenosine 5'-triphosphate (ATP), inosine 5'-triphosphate (ITP) and uridine 5'-triphosphate (UTP) to their corresponding cyclic nucleoside 3':5'-cyclic monophosphates (cNMPs). In relation to cGMP-synthesis cAMP-, cIMP- and cUMP-production amounted to 8%, 26% and 3.5%, respectively. To this end, we have not detected cCMP or cTMP production. Cytosine 5' triphosphate (CTP) and thymidine 5'-triphosphate (TTP) will be further examined as potential sGC substrates following method optimization regarding incubation time and protein concentration.


Our results show that sGC has broader substrate specificity than previously assumed. We could demonstrate that not only bacterial toxins [see poster: M Göttle et al.] but also a mammalian enzyme of high physiological importance catalyses the biosynthesis of rare cNMPs such as cUMP and cIMP.


  1. 1.
    Gille A, Lushington GH, Mou TC, Doughty MB, Johnson RA, Seifert R: Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem. 2004, 279: 19955-19969. 10.1074/jbc.M312560200.CrossRefPubMedGoogle Scholar

Copyright information

© Rauch et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • Kerstin Rauch
    • 1
  • Johannes-Peter Stasch
    • 2
  • Volkhard Kaever
    • 1
  • Roland Seifert
    • 1
  1. 1.Institute of PharmacologyHannover Medical SchoolHannoverGermany
  2. 2.Institute of Cardiovascular ResearchBayer HealthCareWuppertalGermany

Personalised recommendations